Thryv Therapeutics Inc. has initiated its pivotal Phase 2/3 Wave II clinical trial for THRV-1268, a novel orally administered SGK1 inhibitor, in adult patients with Long QT Syndrome Type 2 (LQTS2). The launch builds on promising results from the earlier Wave I study and a subsequent clinical investigation, both of which demonstrated meaningful QT interval
Bionpharma Inc. has secured Abbreviated New Drug Application (ANDA) approval from the United States Food and Drug Administration for its generic version of Etravirine tablets, a second-line treatment for HIV-1. Developed in partnership with STEERLife, the formulation leverages the proprietary FragMelt continuous manufacturing platform to overcome the heat- and shear-sensitivity of the active pharmaceutical ingredient.
AbCellera advances ABCL635 into Phase 2 for hot flashes. Find out what this means for non-hormonal menopause care and the biotech’s GPCR strategy.
Smith+Nephew has signed a definitive agreement to acquire Integrity Orthopaedics, a U.S.-based developer of the Tendon Seam rotator cuff repair system, in a deal worth up to $450 million. The move strengthens the medical device manufacturer’s presence in the sports medicine market by adding a novel repair platform designed to reduce re-tear rates, improve workflow
The U.S. Food and Drug Administration has granted 510(k) clearance to Singular Health Limited’s 3DICOM MD Cloud platform, expanding the Australian company’s regulated product portfolio in the United States. This marks the second FDA approval for the company’s medical imaging software line, following the clearance of its desktop-based 3DICOM MD Viewer in October 2022. The
Find out how Abbisko’s TGCT drug pimicotinib just crossed a major milestone with the FDA—and what this means for patients and the CSF-1R class.
insitro has announced the acquisition of CombinAbleAI and launched its new TherML platform, a modality-agnostic, AI-powered system that integrates small molecules, oligonucleotides, and biologics into a unified therapeutic design stack. The move signals a strategic attempt to industrialize AI-native drug discovery across modalities while reducing late-stage attrition risks. What makes this acquisition different from typical
Find out why Oncolytics Biotech’s latest GOBLET cohort 4 data could reshape immunotherapy strategies for third-line anal cancer.
Find out how Actuate Therapeutics’ elraglusib Phase 2 data at ASCO GI 2026 could change first-line treatment strategies for metastatic pancreatic cancer.
ZYUS Life Sciences launches a C$15–16 million LIFE offering to advance cannabinoid drug development and regulatory execution. Find out what it signals.